Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.

ABSTRACT:

Importance

Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of patients with triple-negative breast cancer (TNBC).

Objective

To investigate the effect of capecitabine on long-term survival outcomes of patients with early breast cancer, particularly in subgroups defined by cancer estrogen receptor (ER) and progesterone receptor (PR) content, and HER2 content (human epidermal growth factor receptor 2).

Design, setting, and participants

This is an exploratory analysis of the multicenter FinXX randomized clinical trial that accrued 1500 women in Finland an

SUBMITTER: Joensuu H 

PROVIDER: S-EPMC5824321 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature